kras g12d

Showing 1 - 5 of 5

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation, Vascular Malformations Trial in Parkville (Alpelisib,

Not yet recruiting
  • Slow-Flow Vascular Malformation
  • +17 more
  • Parkville, Victoria, Australia
    The Royal Children's Hospital
Aug 7, 2023

NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +32 more
  • (no location specified)
Mar 30, 2023

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +14 more
  • ELI-002 7P
  • (no location specified)
Feb 3, 2023

Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

Recruiting
  • Minimal Residual Disease
  • +11 more
  • ELI-002 2P
  • Duarte, California
  • +10 more
Jan 18, 2023

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022